The San Diego-based genomic analysis firm reported $3.3 million in revenue, driven by growth in North America sales, offset by a decline in international sales.
The acquisition will allow the firms to provide annotated biospecimens, as well as sequencing, bioinformatics, and lab services to hospitals and clinicians.
The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
NEW YORK (GenomeWeb) – CombiMatrix is developing two new tests that will expand its place in the reproductive health market, one of which will complement existing chromosomal microarray analysis services and the other of which will open CombiMatrix up to a new market segment.
NEW YORK (GenomeWeb News) – CombiMatrix today announced a 13 percent spike in first quarter revenues, driven by a 34 percent jump in sales generated by its prenatal chromosomal microarray analysis testing services.
NEW YORK (GenomeWeb) – PerkinElmer will continue to sell microarrays and software developed by Signature Genomics, despite its decision to shutter the company's laboratory services business.
NEW YORK (GenomeWeb) - While chromosomal microarray analysis has become the first-tier cytogenetic test for diagnosing individuals with constitutional abnormalities around the world, geneticists continue to struggle with a high level of findings of unknown significance.
Affymetrix has provided more information about how it achieved US Food and Drug Administration clearance for its CytoScan Dx Assay chromosomal microarray analysis offering.
Chromosomal microarray analysis may be widely regarded as a first-tier method for both pediatric and prenatal cytogenetic testing, but that hasn't convinced some insurers to reimburse such tests.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.
